The challenge of reproducing complex disease models in iPSC-derived cells

The challenge of reproducing complex disease models in iPSC-derived cells

Presented by: Dr Steven Broadbent

As we know, neurodegenerative diseases are a major global health issue, yet the drug development process is notoriously slow with 99.6% of potential new therapies for Alzheimer’s Disease (AD) alone failing and thus, not reaching the market. With such high failure rates, there is an urgent need for better human-relevant models of such diseases in order to de-risk drug discovery and improve the bench-to-clinic translation gap.

As world leaders in manufacturing iPSCs consistently and at scale, we wanted to provide the opportunity for our community to ask questions and learn more about the power iPSCs can have even in the midst of the lingering complex challenges that exist within drug development for neurodegenerative diseases.

Dr Steven Broadbent discussed in this webinar:

• iPSCs and the pursuit of ‘more human relevant’ models
  
• Building in vitro models – best practice around lines, cells, assays
  
• The challenge of translational relevance of iPSCs in more complex disease models